VACCINEX

Vaccinex, Inc. (Nasdaq: VCNX) is pioneering a differentiated approach to treating cancer and neurologic diseases through the inhibition of semaphorin 4D (SEMA4D). SEMA4D is a potent biological effector that is believed to prevent immune infiltration and induce myeloid suppressor cells in tumors and also triggers neuroinflammation through reactive gliosis in the brain. The company's lead drug candidate, pepinemab, blocks SEMA4D and has potential to increase immune activity against tumors and to reprogram underlying pathogenic immune mechanisms that amplify damage in chronic neurological disorders such as Azheimer's and Huntington's disease... In 2020/2021 Vaccinex reported results of the SIGNAL phase 2 study of pepinemab in subjects with early manifest or late prodromal Huntington's disease randomized for 18-months, double-blind treatment with single agent pepinemab or placebo. Although the study did not meet the pre-specified primary endpoints, the results indicated significant..

Also known as: Vaccinex, Inc.

Primary location: Rochester United States